Oct 23, 2025
Enamine contributes to the discovery of promising broad-spectrum coronavirus antiviral
Enamine, a leading chemistry and R&D services company, today announced that it was a key synthetic chemistry contributor to a first-of-its-kind, open-science approach that led to the development of a promising broad-spectrum coronavirus antiviral pre-clinical candidate. Enamine's chemistry platform delivered over 2,000 new compounds during the early stages of the programme that resulted in the discovery of pre-clinical candidate ASAP-0017445. The candidate is designed to be a direct-to-generic, globally accessible treatment ready for future coronavirus pandemics.
Read More
Oct 22, 2025
Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.
Expert Systems Inc., a leading life sciences accelerator, announced its continued support for Traws Pharma (NASDAQ: TRAW) as the company initiates Phase 2 clinical studies of Ratutrelvir (TRX01), a next-generation oral antiviral designed to treat newly diagnosed COVID-19 patients.
Read More
Oct 22, 2025
ENA Respiratory secures US$22.4m to advance nasal spray therapy
ENA Respiratory has raised US$22.4m (AU$34m) in Series B financing to support the phase 2 clinical development of its nasal spray therapy, INNA-051.
Read More
